Tarhini AA - Search Results

1

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Tarhini AA, et al. J Clin Oncol. 2020 Feb 20;38(6):567-575. doi: 10.1200/JCO.19.01381. Epub 2019 Dec 27. J Clin Oncol. 2020. PMID: 31880964 Free PMC article. Clinical Trial.

2

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.

Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L. Kirkwood JM, et al. J Clin Oncol. 2002 Sep 1;20(17):3703-18. doi: 10.1200/JCO.2002.03.052. J Clin Oncol. 2002. PMID: 12202672 Review.

3

Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.

Kirkwood JM, Tarhini AA. Kirkwood JM, et al. Among authors: tarhini aa. Forum (Genova). 2003;13(2):127-40; quiz 187-8. Forum (Genova). 2003. PMID: 14732880 Review.

4

Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma?

Tarhini AA, Land S, Gupta A, Kirkwood JM. Tarhini AA, et al. Nat Clin Pract Oncol. 2005 May;2(5):240-1. doi: 10.1038/ncponc0175. Nat Clin Pract Oncol. 2005. PMID: 16264957 No abstract available.

5

Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b".

Tarhini AA, Shipe-Spotloe J, DeMark M, Agarwala SS, Kirkwood JM. Tarhini AA, et al. Oncologist. 2006 May;11(5):538-9; author reply 539-40. doi: 10.1634/theoncologist.11-5-538. Oncologist. 2006. PMID: 16720861 Free article. No abstract available.

6

Oblimersen in the treatment of metastatic melanoma.

Tarhini AA, Kirkwood JM. Tarhini AA, et al. Future Oncol. 2007 Jun;3(3):263-71. doi: 10.2217/14796694.3.3.263. Future Oncol. 2007. PMID: 17547520 Review.

7

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.

Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS. Tarhini AA, et al. J Clin Oncol. 2007 Sep 1;25(25):3802-7. doi: 10.1200/JCO.2006.10.2822. J Clin Oncol. 2007. PMID: 17761969 Clinical Trial.

8

Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.

Tarhini AA, Kirkwood JM. Tarhini AA, et al. Curr Opin Mol Ther. 2007 Oct;9(5):505-14. Curr Opin Mol Ther. 2007. PMID: 17932815 Review.

9

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.

Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC. Kirkwood JM, et al. Among authors: tarhini aa. Nat Clin Pract Oncol. 2008 Jan;5(1):2-3. doi: 10.1038/ncponc1004. Epub 2007 Nov 13. Nat Clin Pract Oncol. 2008. PMID: 18030300 No abstract available.

10

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.

Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM. Hauschild A, et al. Cancer. 2008 Mar 1;112(5):982-94. doi: 10.1002/cncr.23251. Cancer. 2008. PMID: 18236459 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

197 results

Search Page